Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
NCT ID: NCT04359680
Last Updated: 2024-06-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1407 participants
INTERVENTIONAL
2020-05-13
2021-04-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
NCT05157269
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
NCT04489381
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT02612922
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
NCT06817096
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
NCT03336619
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nitazoxanide
Two NTZ 300 mg tablets orally twice daily for 6 weeks.
Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for six weeks
Vitamin Super B-Complex
Vitamin Super B-Complex administered orally twice daily to maintain the blind
Placebo
Two placebo tablets orally twice daily for 6 weeks.
Placebo
Placebo administered orally twice daily for six weeks
Vitamin Super B-Complex
Vitamin Super B-Complex administered orally twice daily to maintain the blind
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for six weeks
Placebo
Placebo administered orally twice daily for six weeks
Vitamin Super B-Complex
Vitamin Super B-Complex administered orally twice daily to maintain the blind
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Persons at increased risk of contracting COVID-19, including:
1. Healthcare workers with known direct occupational exposure to COVID-19 within 7 days prior to enrollment. A qualifying person (i) provides healthcare to patients and/or (ii) typically positions themselves within 6 feet of patients ("close contact") and (iii) is a full- time employee (average of ≥ 24 hours/week) in a high contact area (Emergency Department, Intensive Care Unit, COVID-specific Care Unit, Walk-in Clinic, Paramedic/First Responder).
2. Persons participating in social activities without the practice of generally accepted social distancing practices at least three times per week. Qualifying activities include the presence of at least 10 people in close (\<6 feet) proximity to each other without masks or other personal protective equipment (e.g., socializing at bars or community/social centers, in-home social gatherings, classes or trainings, etc.). These subjects must have engaged in such activities at least three times in the past 7 days and plan to continue these activities during the study.
3. Must have a smartphone, tablet, computer, or other qualifying internet- enabled device and daily internet access.
4. Occupational exposure to a person infected with SAR-CoV-2 within 7 days prior to enrollment or social interaction as defined in criterion 2(b).
5. Willing and able to provide written informed consent and comply with the requirements of the protocol, including completion of the subject diary.
Exclusion Criteria
2. Subjects with known severe heart, lung, neurological or other systemic disease that the Investigator believes could preclude safe participation.
3. Subjects with a history of COVID-19 or known to have developed anti- SARS-CoV-2 antibodies or received a SARS-CoV-2 vaccine.
4. Subjects who experienced a previous episode of acute upper respiratory tract infection, otitis, bronchitis or sinusitis or received antibiotics for these conditions or antiviral therapy for influenza within two weeks prior to and including study day 1.
5. Subjects residing in the same household with another family member currently participating in the study.
6. Receipt of any dose of NTZ within 7 days prior to screening.
7. Treatment with any investigational drug or vaccine therapy within 30 days prior to screening and willing to avoid them during the course of the study.
8. Known sensitivity to NTZ or any of the excipients comprising the study medication.
9. Subjects unable to swallow oral tablets or capsules.
10. Females of childbearing potential who are either pregnant or sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post-treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycle prior to study drug administration, an (intrauterine device) IUD, or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral oophorectomy.
11. Females who are breastfeeding.
12. Subjects with active respiratory allergies or subjects expected to require anti-allergy medications during the study period for respiratory allergies.
13. Subjects taking medications considered to be major CYP2C8 substrates.
14. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol including completion of the subject diary.
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Romark Laboratories L.C.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HealthStar Research LLC
Hot Springs, Arkansas, United States
So Cal Clinical Research
Huntington Beach, California, United States
Long Beach Clinical Trials, LLC
Long Beach, California, United States
Meris Clinical Research
Brandon, Florida, United States
Invesclinica US LLC
Fort Lauderdale, Florida, United States
The Chappel Group Research
Kissimmee, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
DMI Research
Pinellas Park, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Chicago Clinical Research Institute, Inc.
Chicago, Illinois, United States
Chicago Medical Research Institute, Inc.
Chicago, Illinois, United States
Quad Clinical Research
Chicago, Illinois, United States
Chicago Medical Research, LLC
Hazel Crest, Illinois, United States
Centex Studies, Inc.
Lake Charles, Louisiana, United States
Vida Clinical Studies
Dearborn, Michigan, United States
Beacom Family Health Connection
Fremont, Nebraska, United States
North Jersey Community Research Initiative
Newark, New Jersey, United States
Integrative Clinical Trials LLC
Brooklyn, New York, United States
The New York Center for Travel and Tropical Medicine
New York, New York, United States
RH Medical Urgent Care Professional PLLC
The Bronx, New York, United States
Centex Studies, Inc.
Houston, Texas, United States
SMS Clinical Research LLC
Mesquite, Texas, United States
LinQ Research LLC
Pearland, Texas, United States
Rio Grande Valley Clinical Research Institute
Pharr, Texas, United States
BFHC Research
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RM08-3007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.